Screen for the HLA-B*5701 allele prior to initiating therapy with TRIUMEQ [see BOXED WARNING, WARNINGS AND PRECAUTIONS].
TRIUMEQ is a fixed-dose combination product containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. The recommended dosage regimen of TRIUMEQ in adults is one tablet once daily orally with or without food.
The dolutegravir dose (50 mg) in TRIUMEQ is insufficient when coadministered with medications listed in Table 1 that may decrease dolutegravir concentrations; the following dolutegravir dosage regimen is recommended.
Table 1: Dosing Recommendations for TRIUMEQ with Coadministered Medications 
Because TRIUMEQ is a fixed-dose tablet and cannot be dose adjusted, TRIUMEQ is not recommended in:
